142 related articles for article (PubMed ID: 33612375)
1. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Should Chromophobe Renal Cell Carcinoma Be Graded?
Delahunt B; Samaratunga H; Egevad L
Eur Urol; 2021 May; 79(5):e141-e142. PubMed ID: 33612375
[No Abstract] [Full Text] [Related]
2. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Two-, Three-, or Four-tiered Grading of Chromophobe Renal Cancer: That's the Question!
Ohashi R; Hartmann A; Martignoni G; Moch H
Eur Urol; 2021 Jul; 80(1):e17-e18. PubMed ID: 33934927
[No Abstract] [Full Text] [Related]
3. Reply to Riuko Ohashi, Arndt Hartmann, Holger Moch, and Guido Martignoni's Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31: Two-, Three-, or Four-tiered Grading of Chromophobe Renal Cancer: That's the Question!
Avulova S; Cheville JC; Lohse CM; Thompson RH; Potretzke AM
Eur Urol; 2021 Jul; 80(1):e19. PubMed ID: 33875305
[No Abstract] [Full Text] [Related]
4. Reply to Brett Delahunt, Hemamali Samaratunga, Lars Egevad's Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225-31. Should Chromophobe Renal Cell Carcinoma Be Graded?
Avulova S; Cheville JC; Lohse CM; Potretzke AM
Eur Urol; 2021 May; 79(5):e143-e144. PubMed ID: 33637366
[No Abstract] [Full Text] [Related]
5. Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766-72: Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Takahashi T
Eur Urol; 2019 Sep; 76(3):e65-e66. PubMed ID: 31164251
[No Abstract] [Full Text] [Related]
6. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
Avulova S; Cheville JC; Lohse CM; Gupta S; Potretzke TA; Tsivian M; Thompson RH; Boorjian SA; Leibovich BC; Potretzke AM
Eur Urol; 2021 Feb; 79(2):225-231. PubMed ID: 33172723
[TBL] [Abstract][Full Text] [Related]
7. Re: Outcomes following partial nephrectomy by tumor size P. L. Crispen, S. A. Boorjian, C. M. Lohse, T. S. Sebo, J. C. Cheville, M. L. Blute and B. C. Leibovich J Urol 2008; 180: 1912-1917.
Cimen HI; Serefoglu EC; Balbay MD
J Urol; 2009 Sep; 182(3):1232; author reply 1232. PubMed ID: 19625039
[No Abstract] [Full Text] [Related]
8. External validation of a four-tiered grading system for chromophobe renal cell carcinoma.
Liu S; Hou M; Yao Y; Mei J; Sun L; Zhang G
Clin Exp Med; 2024 Mar; 24(1):61. PubMed ID: 38554222
[TBL] [Abstract][Full Text] [Related]
9. Reply to Takeshi Takahashi's Letter to the Editor re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting functional outcomes after partial and radical nephrectomy. Eur Urol 2019;75:766-72. Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Bhindi B; Lohse CM; Schulte PJ; Mason RJ; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2019 Sep; 76(3):e67-e68. PubMed ID: 31167750
[No Abstract] [Full Text] [Related]
10. Re: Todd M. Morgan, Dominic Tang, Kelly L. Stratton, et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011;59:923-8. Re: Umberto Capitanio, Francesco Montorsi. Does preoperative nutritional status affect survival in renal cell carcinoma? The debate continues. Eur Urol 2011;59:929-30.
Brookman-May S; Burger M; Wieland WF; May M
Eur Urol; 2011 Nov; 60(5):e45-6; author reply e47. PubMed ID: 21820239
[No Abstract] [Full Text] [Related]
11. Re: Carlo Bravi, Emily Vertosick, Nicole Benfante, et al. Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy. Eur Urol 2019;76:398-403.
Kim WH; Yoon HK; Jeong CW
Eur Urol; 2020 Jan; 77(1):e14-e15. PubMed ID: 31586511
[No Abstract] [Full Text] [Related]
12. Re: Robert J. Motzer, Pratik P. Rane, Todd L. Saretsky, et al. Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review. Eur Urol. Eur Urol. 2023;84:406-17.
Gutiérrez Rojas AF; Fernández D; Diaz Ritter C
Eur Urol; 2024 Mar; 85(3):e94. PubMed ID: 37802682
[No Abstract] [Full Text] [Related]
13. Re: outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy: R. H. Breau, P. L. Crispen, R. E. Jimenez, C. M. Lohse, M. L. Blute and B. C. Leibovich J Urol 2010; 183: 903-908.
Cimen HI; Canda AE; Balbay MD
J Urol; 2010 Nov; 184(5):2212; author reply 2212-3. PubMed ID: 20864129
[No Abstract] [Full Text] [Related]
14. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
[No Abstract] [Full Text] [Related]
15. Re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9.
Mouracade P
Eur Urol; 2015 Oct; 68(4):e82-3. PubMed ID: 26033152
[No Abstract] [Full Text] [Related]
16. Re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-9.
Potretzke AM; Larson JA; Bhayani SB
Eur Urol; 2015 Feb; 67(2):e19-20. PubMed ID: 25269382
[No Abstract] [Full Text] [Related]
17. Re: R. Houston Thompson, Tom Atwell, Grant Schmit, et al. Comparison of Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2015;67:252-9.
Zargar H; Coelho RF; Kaouk JH
Eur Urol; 2015 Feb; 67(2):e23. PubMed ID: 25266972
[No Abstract] [Full Text] [Related]
18. Re: Hiury S. Andrade, Homayoun Zargar, Peter A. Caputo, et al. Five-year Oncologic Outcomes After Transperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma. Eur Urol 2016;69:1149-54.
Shin TY; Abdel Raheem A; Rha KH
Eur Urol; 2016 Oct; 70(4):e100-e101. PubMed ID: 26995331
[No Abstract] [Full Text] [Related]
19. Re: Maxine Sun, Quoc-dien Trinh, Marco Bianchi, et al. A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol 2012;61:725-31.
Sandhu GS; Tanagho YS; Bhayani SB
Eur Urol; 2012 Sep; 62(3):e58; author reply e59-60. PubMed ID: 22704368
[No Abstract] [Full Text] [Related]
20. Reply to Steven C. Campbell, Chalairat Suk-Ouichai, and Yun-Lin Ye's Words of Wisdom re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Antonelli A, Minervini A, Sandri M, et al. Eur Urol 2018;74:661-7 and 2019;75:198.
Antonelli A; Minervini A; Capitanio U
Eur Urol; 2019 Jul; 76(1):e17-e18. PubMed ID: 30711331
[No Abstract] [Full Text] [Related]
[Next] [New Search]
